Intellia Therapeutics stock surged nearly 10% pre-market after the FDA lifted the clinical hold on its Phase 3 MAGNITUDE trial for the heart drug nex-z. The trial resumes with new safety measures agreed upon by the FDA, including closer liver monitoring and stricter patient screening following previous side effects.